11 research outputs found

    MOESM2 of Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes

    No full text
    Additional file 2: Table S1. Models of MetS (and MetS severity) in individuals with diabetes on incident CHD. Table S2. Models of MetS (and MetS severity) in individuals with diabetes on incident CHD by time of diabetes diagnosis. Table S3. Models of standard MetS severity in individuals with baseline diabetes on incident CHD with and without inclusion of HbA1c at Visit 2

    MOESM1 of Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes

    No full text
    Additional file 1: Figure S1. Levels of the individual MetS components by timing of diabetes diagnosis. Model-generated values of A). waist circumference, B). systolic blood pressure, C). HDL-cholesterol, D). fasting triglycerides, and E). fasting glucose for participants with diabetes at baseline (Visit 1), and those diagnosed by Visits 2, 3, and 4, compared to those never diagnosed. All models were stratified by site and included age (at baseline), sex, and race as covariates. Figure S2. No-glucose MetS severity Z-scores by sex and race. Model-generated values for A). standard and B). no-glucose MetS severity Z-scores for participants with diabetes at baseline (Visit 1), and those diagnosed by Visits 2, 3, and 4, compared to those never diagnosed. All models were stratified by site and included age (at baseline), sex, and race as covariates

    Fecal MPO, Fecal alpha-1-antitrypsin (A1AT), and plasma LPS, FABP and SAA each predicts subsequent growth impairment.

    No full text
    <p>a: For MPO, <i>p</i> = 0.028; n = 266 when correcting for age and gender, and independent of breastfeeding status (that showed no correlation in these 6-26m old children) and of age. b: For A1AT, n = 237; <i>p</i> = 0.042; and A1AT also correlates with “catchup WAZ” as well, <i>p</i> = 0.035 after correcting for age and gender. c: For urine L/M, higher values correlated (controlling for age and gender) with impaired growth (delta HAZ) (<i>r</i> = -0.173; <i>p</i> = 0.009; n = 230). d: For plasma LPS (ie lower LUM), higher values correlated with impaired growth (delta HAZ) (<i>r</i> = 0.151; <i>p</i> = 0.017; n = 251). e: For plasma FABP, higher values correlated with impaired growth (delta HAZ) (r = -0.134; <i>p</i> = 0.042; n = 231). f: For plasma SAA, higher values correlated with impaired growth (delta HAZ) (r = -0.132; p = 0.046; n = 231).</p
    corecore